Andrew Dunn, MD, MPH, MACP, SFHM; Henry S. Sacks, PhD, MD, FACP
Dunn A, Sacks HS. In at-risk medical patients, rivaroxaban after discharge did not reduce symptomatic or fatal VTE at 45 days. Ann Intern Med. 2018;169:JC64. doi: https://doi.org/10.7326/ACPJC-2018-169-12-064
Download citation file:
Published: Ann Intern Med. 2018;169(12):JC64.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use